Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Argus Health
Federal Trade Commission
Medtronic
Deloitte
Queensland Health
Citi
Merck
McKinsey

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021492

« Back to Dashboard

NDA 021492 describes ELOXATIN, which is a drug marketed by Sanofi Aventis Us and is included in two NDAs. It is available from three suppliers. Additional details are available on the ELOXATIN profile page.

The generic ingredient in ELOXATIN is oxaliplatin. There are twenty-six drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the oxaliplatin profile page.
Summary for 021492
Tradename:ELOXATIN
Applicant:Sanofi Aventis Us
Ingredient:oxaliplatin
Patents:0
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;IV (INFUSION)Strength50MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Aug 9, 2002TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;IV (INFUSION)Strength100MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**
Approval Date:Aug 9, 2002TE:RLD:Yes

Expired US Patents for NDA 021492

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021492-002 Aug 9, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021492-002 Aug 9, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021492-001 Aug 9, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Sanofi Aventis Us ELOXATIN oxaliplatin INJECTABLE;IV (INFUSION) 021492-002 Aug 9, 2002 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
US Department of Justice
Fish and Richardson
AstraZeneca
Federal Trade Commission
Chubb
UBS
Cerilliant
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.